Engineered immune cells take on tough cancers in first human trial
NCT ID NCT07488923
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to check the treatment's safety and to see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ML261 (a type of CAR T-cell therapy that targets DLL3 on cancer cells)
- What this could lead to
- If successful, this could lead to a new treatment option for people with certain hard-to-treat lung and neuroendocrine cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a very early, first-in-human trial, so safety and effectiveness are unknown. There is a risk of serious side effects, and the therapy may not work for many participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Sarah Cannon Research Institute (SCRI)
Nashville, Tennessee, 37203, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75235, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at stubborn lung cancer
- Could a hidden nerve condition be more common in lung cancer than we think?
- Can a Triple-Drug combo outsmart a rare and aggressive cancer?
- Can a gentler drug trio tame small cell lung cancer in older patients?
- Experimental combo aims to tackle Treatment-Resistant cancers
- New PET scan targets hidden lung cancer cells